ALA — Arovella Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$61.65m
- AU$47.30m
- AU$0.80m
Brief: Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update
Brief: Arovella Therapeutics Seeks Trading Halt
Brief: Arovella Therapeutics Updates On Ala-101 And Oncarlytics Research Collaboration
Australia's Arovella Therapeutics hits 2-week high after new CFO appointed
Brief: Arovella Therapeutics Announces Appointment of Tim Luscombe As Chief Financial Officer
Brief: Arovella Therapeutics Terminates License Agreement With Md Anderson Cancer Centre
Brief: Arovella Therapeutics Enters Global, Exclusive License With Sparx Group
Australia's Arovella Therapeutics gains on licence to develop cancer cell therapy
Brief: The Sparx Group Enters Into A Collaboration With Arovella Therapeutics For The Development Of Cldn18.2-Car-Inkt Cell Therapy
Brief: Arovella Therapeutics Seeks Trading Halt
Brief: Arovella Therapeutics Says FY Net Loss Attributable A$10.2 Mln
Australia's Arovella Therapeutics hits 2-month low on discounted placement
Brief: Arovella Therapeutics Says Firm Commitments Received For A$4.1 Million Placement
Brief: Arovella Therapeutics Seeks Trading Halt
Brief: Arovella Therapeutics Says Research And Development Facility Closure Reduces costs by A$1.5M Per Annum
Brief: Arovella Therapeutics Says Appointment Of Thomas Duthy As Non-Executive Chair
Brief: Arovella Therapeutics Receives Firm Commitments For A$1.5 Mln Placement At A$0.020 Per Share
Brief: Arovella Therapeutics Seeks Trading Halt
Brief: Arovella Therapeutics Says Europe Patent To Be Granted For Inkt Cell Therapy Platform